1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 9
2 Introduction 10
2.1 Bioabsorbable Stents (BAS) Overview 10
3 Products under Development 11
3.1 Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development 11
3.2 Bioabsorbable Stents (BAS) - Pipeline Products by Territory 12
3.3 Bioabsorbable Stents (BAS) - Pipeline Products by Regulatory Path 13
3.4 Bioabsorbable Stents (BAS) - Pipeline Products by Estimated Approval Date 14
3.5 Bioabsorbable Stents (BAS) - Ongoing Clinical Trials 15
4 Bioabsorbable Stents (BAS) - Pipeline Products under Development by Companies 16
4.1 Bioabsorbable Stents (BAS) Companies - Pipeline Products by Stage of Development 16
4.2 Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development 18
5 Bioabsorbable Stents (BAS) Companies and Product Overview 20
5.1 480 Biomedical Inc Company Overview 20
5.2 Abbott Vascular Inc Company Overview 21
5.3 Amaranth Medical Inc Company Overview 22
5.4 Arterius Ltd Company Overview 30
5.5 Biosensors International Group Ltd Company Overview 31
5.6 Biosten, LLC Company Overview 32
5.7 Biotronik AG Company Overview 33
5.8 Biotronik SE & Co KG Company Overview 38
5.9 Boston Scientific Corp Company Overview 39
5.10 Cardionovum GmbH Company Overview 43
5.11 Cordis Corp Company Overview 44
5.12 HangZhou HuaAn Biotechnology Co., Ltd. Company Overview 45
5.13 Icon Interventional Systems, Inc. Company Overview 46
5.14 Japan Stent Technology Co., Ltd. Company Overview 47
5.15 Kyoto Medical Planning Co Ltd Company Overview 48
5.16 Lepu Medical Technology (Beijing) Co Ltd Company Overview 49
5.17 Lifetech Scientific (Shenzhen) Co Ltd Company Overview 52
5.18 Manli Cardiology Ltd Company Overview 55
5.19 Meril Life Sciences Pvt Ltd Company Overview 56
5.20 Micell Technologies Inc Company Overview 62
5.21 Michigan Technological University Company Overview 67
5.22 MicroPort Scientific Corp Company Overview 68
5.23 Minvasys SAS Company Overview 69
5.24 MIV Therapeutics Inc Company Overview 70
5.25 NanoCoeur, Inc. Company Overview 72
5.26 North Carolina State University Company Overview 73
5.27 Northwestern University Company Overview 74
5.28 OrbusNeich Company Overview 75
5.29 Pediastent LLC Company Overview 77
5.30 QualiMed Innovative Medizinprodukte GmbH Company Overview 78
5.31 REVA Medical Inc Company Overview 79
5.32 S3V Vascular Technologies Company Overview 85
5.33 Shanghai MicroPort Medical Group Co Ltd Company Overview 86
5.34 Tepha Inc Company Overview 89
5.35 University of Alabama at Birmingham Company Overview 90
5.36 University of Florida Company Overview 91
5.37 VasoTech Inc. Company Overview 92
5.38 Xenogenics Corporation Company Overview 93
6 Bioabsorbable Stents (BAS) - Recent Developments 96
6.1 May 24, 2018: Reva Symposium Showcases Clinical Data 96
6.2 May 23, 2018: Fantom’s Positive Two-Year Results Show Sustained Safety and Efficacy 96
6.3 May 23, 2018: Positive Two-Year Data from MiStent DESSOLVE III Trial Presented at EuroPCR - Excellent Safety And Low Target Lesion Revascularization (TLR) Rates Persist 98
6.4 May 23, 2018: Amaranth Presented Interim Nine-Month Follow-up MAGNITUDE (98 micron) and Two-Year Follow-up APTITUDE (115 micron) Data at EuroPCR Symposium 99
6.5 May 23, 2018: Fantom’s Positive Two-Year Results Show Sustained Safety and Efficacy 100
6.6 May 17, 2018: Mr. Jonathan Chen Promoted to Chief International Business Officer of MPSC 101
6.7 May 16, 2018: Reva Announces First Implant Of The Fantom Bioresorbable Scaffold In Turkey 101
6.8 May 11, 2018: Terumo Appoints its U.S.-based Subsidiary's Associate as the Fifth Terumo Fellow 102
6.9 May 09, 2018: Reva Medical Announces First Quarter 2018 Financial Results 102
6.10 Apr 25, 2018: Boston Scientific Reports Financial Results For First Quarter 2018 104
6.11 Apr 25, 2018: Xianjian Technology Receives the Most Attention from Institutional Investors 106
6.12 Apr 16, 2018: REVA to Present Full Two-Year FANTOM II Data at EuroPCR 106
6.13 Apr 02, 2018: REVA Initiates Commercial Distribution Partnership in Turkey 107
6.14 Mar 28, 2018: MicroPort Scientific Announces 2017 Annual Results 107
6.15 Mar 27, 2018: REVA Announces First Implant of the Fantom Encore Bioresorbable Scaffold in Switzerland 109
6.16 Mar 27, 2018: MicroPort Scientific Announces Year Ended 31 December 2017 Financial Results 110
6.17 Mar 20, 2018: Micell Technologies Announces Expanded Patent Estate 110
6.18 Mar 08, 2018: REVA Medical Reports Fourth Quarter and Full Year 2017 Financial Results 111
6.19 Mar 01, 2018: GTX Launches $99.00 Easy Start Plan for GPS SmartSole and Economy Service Plan as low as $14.95 113
6.20 Mar 01, 2018: Study finds the best stent for treatment following a heart attack 114
6.21 Feb 26, 2018: Reva Announces CE Mark And First Implant Of The Fantom Encore Bioresorbable Scaffold 115
6.22 Feb 08, 2018: Terumo Revises the Full-Year Results Forecast for FY 2017 116
6.23 Feb 08, 2018: MicroPort Signs Strategic Agreement with Neptunus Biotechnology 117
6.24 Feb 05, 2018: Reva Appoints Stephen Oesterle As Board Of Directors 117
6.25 Feb 01, 2018: REVA Medical: Quarter Ended 31 December 2017 118
6.26 Feb 01, 2018: Boston Scientific Announces Results for Fourth Quarter and Full Year 2017 119
6.27 Jan 25, 2018: REVA Announces First Implant of the Fantom Bioresorbable Scaffold in Italy 121
6.28 Jan 25, 2018: Terumo Announces Change of Directors and Executive Officers 121
6.29 Jan 09, 2018: Positive Five-Year Data Published for MiStent in EuroIntervention 123
6.30 Jan 09, 2018: MicroPort Selected as "2017 China Innovative Medical Device Company" 124
6.31 Jan 09, 2018: MicroPort Awarded 2017 Shanghai Pilot Enterprise with Outstanding Innovation 124
6.32 Jan 09, 2018: Boston Scientific Announces Preliminary Unaudited Sales For The Fourth Quarter And Full Year Ended December 31, 2017 125
6.33 Jan 07, 2018: LifeTech Scientific and Ally Bridge Group Form China-Global Medtech Investment and Operating Partnership 125
7 Appendix 150
7.1 Methodology 150
7.2 About GlobalData 153
7.3 Contact Us 153
7.4 Disclaimer 153

1.1 List of Tables
Table 1: Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development 12
Table 2: Bioabsorbable Stents (BAS) - Pipeline Products by Territory 13
Table 3: Bioabsorbable Stents (BAS) - Pipeline Products by Regulatory Path 14
Table 4: Bioabsorbable Stents (BAS) - Pipeline Products by Estimated Approval Date 15
Table 5: Bioabsorbable Stents (BAS) - Ongoing Clinical Trials 16
Table 6: Bioabsorbable Stents (BAS) Companies - Pipeline Products by Stage of Development 17
Table 7: Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development 19
Table 8: 480 Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview 21
Table 9: Absorbable Scaffold Stent - Neonatal Aortic Coarctation - Product Status 21
Table 10: Absorbable Scaffold Stent - Neonatal Aortic Coarctation - Product Description 21
Table 11: Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview 22
Table 12: Second Generation Bioresorbable Vascular Scaffold - Product Status 22
Table 13: Second Generation Bioresorbable Vascular Scaffold - Product Description 22
Table 14: Amaranth Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 23
Table 15: 80-micron MAGNITUDE Bioresorbable Scaffold - Product Status 23
Table 16: 80-micron MAGNITUDE Bioresorbable Scaffold - Product Description 23
Table 17: APTITUDE Sirolimus-Eluting Bioresorbable Scaffold - Product Status 24
Table 18: APTITUDE Sirolimus-Eluting Bioresorbable Scaffold - Product Description 24
Table 19: FORTITUDE Scaffold - Product Status 24
Table 20: FORTITUDE Scaffold - Product Description 25
Table 21: MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold - Product Status 25
Table 22: MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold - Product Description 25
Table 23: Second Generation FORTITUDE Scaffold - Product Status 26
Table 24: Second Generation FORTITUDE Scaffold - Product Description 26
Table 25: Amaranth Medical Inc - Ongoing Clinical Trials Overview 27
Table 26: FORTITUDE Scaffold - Amaranth Endovascular Study of a Drug-eluting Bioresorbable Coronary Scaffold 28
Table 27: FORTITUDE Scaffold - Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - European Trial 28
Table 28: APTITUDE Sirolimus-Eluting Bioresorbable Scaffold - Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - Extended Trial II 29
Table 29: MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold - Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - Extended Trial III 30
Table 30: Arterius Ltd Pipeline Products & Ongoing Clinical Trials Overview 31
Table 31: Arteriosorb Absorbable Drug-Eluting Scaffold - Product Status 31
Table 32: Arteriosorb Absorbable Drug-Eluting Scaffold - Product Description 31
Table 33: Biosensors International Group Ltd Pipeline Products & Ongoing Clinical Trials Overview 32
Table 34: Sparrow Drug Eluting Stent System - Product Status 32
Table 35: Sparrow Drug Eluting Stent System - Product Description 32
Table 36: Biosten, LLC Pipeline Products & Ongoing Clinical Trials Overview 33
Table 37: Biodegradable Endovascular Implant - Product Status 33
Table 38: Biodegradable Endovascular Implant - Product Description 33
Table 39: Biotronik AG Pipeline Products & Ongoing Clinical Trials Overview 34
Table 40: Magmaris Bioresorbable Magnesium Scaffold - Product Status 34
Table 41: Magmaris Bioresorbable Magnesium Scaffold - Product Description 34
Table 42: Biotronik AG - Ongoing Clinical Trials Overview 35
Table 43: Magmaris Bioresorbable Magnesium Scaffold - A Sirolimus Eluting Bioresorbable Magnesium Stent for Treatment of Coronary Bifurcation Lesions: The BIFSORB Pilot Study II 36
Table 44: Magmaris Bioresorbable Magnesium Scaffold - BIOTRONIK - Safety and Clinical Performance of the Drug Eluting Absorbable Metal Scaffold (DREAMS 2nd Generation) in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries: BIOSOLVE-II 36
Table 45: Magmaris Bioresorbable Magnesium Scaffold - BIOTRONIKS - Acute Performance of a Drug Eluting Absorbable Metal Scaffold (DREAMS 2G) in Patients with de Novo Lesions in Native Coronary Arteries: BIOSOLVE-III 36
Table 46: Magmaris Bioresorbable Magnesium Scaffold - Biotroniks - Safety and Performance in de Novo Lesion of Native Coronary Arteries with Magmaris- Registry: BIOSOLVE-IV 37
Table 47: Magmaris Bioresorbable Magnesium Scaffold - Coronary Artery Healing Process after Bioresorbable Scaffold in Patients with Non-ST-segment Elevation Myocardial Infarction (NSTEMI) 37
Table 48: Magmaris Bioresorbable Magnesium Scaffold - Magnesium-based Bioresorbable Scaffold and Vasomotor Function in Patients with Acute ST Segment Elevation Myocardial Infarction 37
Table 49: Magmaris Bioresorbable Magnesium Scaffold - Optical Coherence Tomography Evaluation of Bioabsorbable Vascular Scaffold Technique with Magmaris 38
Table 50: Magmaris Bioresorbable Magnesium Scaffold - Prospective Observational Registry of Patients with a Bioabsorbable Magnesium Stent Implant -MAGMARIS- in Usual Clinical Practice 38
Table 51: Magmaris Bioresorbable Magnesium Scaffold - Scaffold Implantation in Emilia-Romagna 38
Table 52: Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview 39
Table 53: AMS-2 - Product Status 39
Table 54: AMS-2 - Product Description 39
Table 55: Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 40
Table 56: Fully Resorbable Drug-Eluting Scaffold System - Product Status 40
Table 57: Fully Resorbable Drug-Eluting Scaffold System - Product Description 40
Table 58: Next Generation SYNERGY - Product Status 41
Table 59: Next Generation SYNERGY - Product Description 41
Table 60: Boston Scientific Corp - Ongoing Clinical Trials Overview 42
Table 61: Fully Resorbable Drug-Eluting Scaffold System - Fully Absorbable Scaffold Feasibility Study 43
Table 62: Cardionovum GmbH Pipeline Products & Ongoing Clinical Trials Overview 44
Table 63: CARDIOSORB - Product Status 44
Table 64: CARDIOSORB - Product Description 44
Table 65: Cordis Corp Pipeline Products & Ongoing Clinical Trials Overview 45
Table 66: SymBio Pimecrolimus/Paclitaxel-eluting Stent - Product Status 45
Table 67: SymBio Pimecrolimus/Paclitaxel-eluting Stent - Product Description 45
Table 68: HangZhou HuaAn Biotechnology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 46
Table 69: Xinsorb BRS - Product Status 46
Table 70: Xinsorb BRS - Product Description 46
Table 71: Icon Interventional Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview 47
Table 72: Biosorb Pediatric Dissolving Stent - Product Status 47
Table 73: Biosorb Pediatric Dissolving Stent - Product Description 47
Table 74: Japan Stent Technology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 48
Table 75: Bioabsorbable Stent - Product Status 48
Table 76: Bioabsorbable Stent - Product Description 48
Table 77: Kyoto Medical Planning Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 49
Table 78: Igaki-Tamai Coronary Stent - Product Status 49
Table 79: Igaki-Tamai Coronary Stent - Product Description 49
Table 80: Lepu Medical Technology (Beijing) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 50
Table 81: NeoVas Bioresorbable Coronary Scaffold (BCS) - Product Status 50
Table 82: NeoVas Bioresorbable Coronary Scaffold (BCS) - Product Description 50
Table 83: Lepu Medical Technology (Beijing) Co Ltd - Ongoing Clinical Trials Overview 51
Table 84: NeoVas Bioresorbable Coronary Scaffold (BCS) - Clinical Evaluation of a Bioresorbable Sirolimus-eluting Coronary Scaffold in the Treatment of Patients with de Novo Coronary Artery Lesion (NeoVas): a Single Arm Registry Study 52
Table 85: NeoVas Bioresorbable Coronary Scaffold (BCS) - Clinical Evaluation of a Bioresorbable Sirolimus-eluting Coronary Scaffold in the Treatment of Patients with Denovo Coronary Artery Lesion (NeoVas): Randomized Controlled Trial 52
Table 86: Lifetech Scientific (Shenzhen) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 53
Table 87: Iron-based Drug-eluting Bioresorbable Coronary Scaffold System - Product Status 53
Table 88: Iron-based Drug-eluting Bioresorbable Coronary Scaffold System - Product Description 53
Table 89: Lifetech Scientific (Shenzhen) Co Ltd - Ongoing Clinical Trials Overview 54
Table 90: Iron-based Drug-eluting Bioresorbable Coronary Scaffold System - A First-in-man Study of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System (IBS) 55
Table 91: Manli Cardiology Ltd Pipeline Products & Ongoing Clinical Trials Overview 56
Table 92: MIRAGE - Product Status 56
Table 93: MIRAGE - Product Description 56
Table 94: Meril Life Sciences Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 57
Table 95: BioMime - Product Status 57
Table 96: BioMime - Product Description 57
Table 97: BIOMIME AURA - Product Status 58
Table 98: BIOMIME AURA - Product Description 58
Table 99: Meril Life Sciences Pvt Ltd - Ongoing Clinical Trials Overview 59
Table 100: BioMime - A Prospective, Active Control, Open-label, Multi-center, Randomized Clinical trial comparing BioMime Branch - Sirolimus Eluting Coronary Side Branch Stent System Versus Xience family of Everolimus Eluting Coronary Stent System to Evaluate Safety and Performance in Patients with de Novo Coronary Bifurcation Lesions 60
Table 101: BioMime - A Prospective, Single-arm, Multi-center, Observational, Real World Registry to Evaluate Safety and Performance of the BioMime Morph Sirolimus Eluting Coronary Stent System for Very Long Coronary Lesions. 60
Table 102: BioMime - Biomime Biosorbable Polymer Sirolimus-eluting Stent in All-comers Patients Treated with Percutaneous Coronary Interventions: The BELLINI Registry 60
Table 103: BioMime - Randomized Study to Evaluate Segmental Late Loss Comparing Two PCI Strategies Using a Long Stent Versus 2 Shorter Stents to Treat Long or Tandem Coronary Stenosis 61
Table 104: BioMime - Real World Drug-eluting Stent Prospective, Open, Multi-site, Registry in Korea: BioMime Stent, Ultimaster Stent Versus Xience Stent by SMart Angioplastry Research Team: SMARTDESK-MX 61
Table 105: BIOMIME AURA - A Prospective, Active Control, Open-label, Multi-center, Randomized Clinical trial comparing BioMime Branch - Sirolimus Eluting Coronary Side Branch Stent System Versus Xience family of Everolimus Eluting Coronary Stent System to Evaluate Safety and Performance in Patients with de Novo Coronary Bifurcation Lesions 62
Table 106: BIOMIME AURA - Randomized Study to Evaluate Segmental Late Loss Comparing Two PCI Strategies Using a Long Stent Versus 2 Shorter Stents to Treat Long or Tandem Coronary Stenosis 62
Table 107: Micell Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 63
Table 108: Bioresorbable Scaffold (BRS) - Product Status 63
Table 109: Bioresorbable Scaffold (BRS) - Product Description 63
Table 110: MiStent SES - Product Status 64
Table 111: MiStent SES - Product Description 64
Table 112: Micell Technologies Inc - Ongoing Clinical Trials Overview 65
Table 113: MiStent SES - A Prospective, Single-blinded, Multi-center, Randomized, Controlled, Registered Clinical Trial on the Efficacy and Safety of Sirolimus-eluting Stent (MiStent System) in the Treatment of Patients with Coronary Heart Disease 66
Table 114: MiStent SES - MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES) Optical Coherence Tomography (OCT) 66
Table 115: MiStent SES - Multicenter Randomized Study of the MiStent Sirolimus Eluting Absorbable Polymer Stent System (MiStent SES) for Revascularization of Coronary Arteries 66
Table 116: MiStent SES - Multicenter Randomized Study of the Mistent Sirolimus Eluting Absorbable Polymer Stent System (MT005) for Revascularization of Coronary Arteries 67
Table 117: Michigan Technological University Pipeline Products & Ongoing Clinical Trials Overview 68
Table 118: Bioabsorbable Stent - Product Status 68
Table 119: Bioabsorbable Stent - Product Description 68
Table 120: MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 69
Table 121: Firefalcon Bioresorbable Device - Product Status 69
Table 122: Firefalcon Bioresorbable Device - Product Description 69
Table 123: Minvasys SAS Pipeline Products & Ongoing Clinical Trials Overview 70
Table 124: Nile LM SIR Sirolimus Eluting Intracoronary Stent - Product Status 70
Table 125: Nile LM SIR Sirolimus Eluting Intracoronary Stent - Product Description 70
Table 126: MIV Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 71
Table 127: Smart-1 DES - Product Status 71
Table 128: Smart-1 DES - Product Description 71
Table 129: Smart-4 DES - Product Status 72
Table 130: Smart-4 DES - Product Description 72

1.2 List of Figures
Figure 1: Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development 12
Figure 2: Bioabsorbable Stents (BAS) - Pipeline Products by Territory 13
Figure 3: Bioabsorbable Stents (BAS) - Pipeline Products by Regulatory Path 14
Figure 4: Bioabsorbable Stents (BAS) - Pipeline Products by Estimated Approval Date 15
Figure 5: Bioabsorbable Stents (BAS) - Ongoing Clinical Trials 16